Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma. - Wikidata - awgldk - TriplyDB

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma.

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma.

http://www.wikidata.org/entity/Q37712826

about

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma.

http://www.wikidata.org/entity/Q37712826

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 March 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Impact of Cytological Sampling ...... ge III-IV Lung Adenocarcinoma.

@en

Impact of Cytological Sampling ...... ge III-IV Lung Adenocarcinoma.

@nl

type

label

Impact of Cytological Sampling ...... ge III-IV Lung Adenocarcinoma.

@en

Impact of Cytological Sampling ...... ge III-IV Lung Adenocarcinoma.

@nl

prefLabel

Impact of Cytological Sampling ...... ge III-IV Lung Adenocarcinoma.

@en

Impact of Cytological Sampling ...... ge III-IV Lung Adenocarcinoma.

@nl

P1433

Q37712826-2037BBC2-4BA9-48FD-8814-6A46A1811C35

P1476

Q37712826-C186A9B9-4490-4D3D-8C61-1806061EA188

P2093

Q37712826-060EF35E-D37A-42AD-831F-2F3C4BB66318

Q37712826-65B3DD42-BAF9-40A1-9427-1946FE629357

Q37712826-8B0E1781-5428-4783-859E-F16E6D0ECAC4

Q37712826-9FB1C061-D30E-40A3-AE63-18654341D01F

Q37712826-FF2D49AA-2E3C-442D-B7F4-C96563C16B9E

P2860

Q37712826-06D833F6-686F-4BF8-902D-F5A6D47D7DB4

Q37712826-1E51A3DB-ECCB-4F60-9F08-657CCC0B6633

Q37712826-26B2199A-D742-4F9A-8E86-85CDE81DA8CC

Q37712826-26F104DC-43CB-451A-A194-4BC007851CB6

Q37712826-2D39F8A6-DBB2-49C9-9032-D7790A734DCC

Q37712826-5875FCD7-FA4B-40AB-ADB6-82E44C0F93E3

Q37712826-58861359-983F-42D1-9C4F-F5597D840FEA

Q37712826-5F583BB3-3FEE-448C-88DA-21D13CA7BF7D

Q37712826-652288AD-5155-4A35-B398-CC053E367204

Q37712826-6621DF48-69CD-4E5F-B058-34024D9F8D64

P304

Q37712826-0CFD5A72-58FE-40A3-B937-A4B1188E6529

P31

Q37712826-61C8CC2A-4C64-4BFD-A7B4-F5C7272351FF

P356

Q37712826-FFB9F716-9ADC-41B6-ABE1-179E834392DD

P478

Q37712826-7AEF5C54-7C2A-4D8B-8AC6-FCC9972E382A

P50

Q37712826-7DEE06D4-7B50-4693-A2D9-6E14ECFA9A13

P577

Q37712826-34D9A947-FEEC-41B6-B24F-812E22A4C87A

P698

Q37712826-AA639C01-784D-4944-A01F-430BB7AA55F9

P921

Q37712826-2D451FB6-C6FC-4104-9923-CE1418A07FF0

P932

Q37712826-2946F5CC-BE89-4809-861B-0211E04E9899

P356

P1433

Lung cancer international

P1476

Impact of Cytological Sampling ...... age III-IV Lung Adenocarcinoma

@en

P2093

Christian Smith

http://www.w3.org/2001/XMLSchema#string

Diane Parry

http://www.w3.org/2001/XMLSchema#string

Gwenllian Edwards

http://www.w3.org/2001/XMLSchema#string

Jason Francis Lester

http://www.w3.org/2001/XMLSchema#string

Rachel Butler

http://www.w3.org/2001/XMLSchema#string

P2860

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

EGFR mutation testing in pulmonary adenocarcinoma: evaluation of tumor cell number and tumor percent in paraffin sections of 120 small biopsies.

Preanalytic parameters in epidermal growth factor receptor mutation testing for non-small cell lung carcinoma: A review of cytologic series

Impact of EBUS-TBNA on modalities for tissue acquisition in patients with lung cancer.

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.

P304

9614938

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/9614938

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

Rhian Siân Davies

P577

2017-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28367333

http://www.w3.org/2001/XMLSchema#string

P921

P932

5359447

http://www.w3.org/2001/XMLSchema#string